Nicox shares soar on Zervi­ate OK; Gem­phire CEO re­signs; Ar­ray, Ono team up on a $187M deal

→  Nicox’s Zervi­ate re­ceived FDA ap­proval to­day and $COX stocks have soared in re­sponse to the an­nounce­ment. The com­pa­ny pre­vi­ous­ly ran in­to trou­ble when a drug it out-li­censed to Bausch + Lomb was de­layed due to in­ad­e­qua­cies at the com­pa­ny’s man­u­fac­tur­ing fa­cil­i­ty. “Re­ceiv­ing ap­proval from the U.S. FDA for Zervi­ate is a huge mile­stone for Nicox and part­ner­ing dis­cus­sions are un­der­way for U.S. com­mer­cial­iza­tion rights,” com­ment­ed Michele Garu­fi, the CEO of Nicox. Shares are up more than 20%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.